Cure My Disease

Don't miss your cure!

 Log in / Sign up

Magic mushroom compound targets loneliness by calming Brain's threat response

NCT ID NCT07693153

Not yet recruiting Symptom relief Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether a single 25 mg dose of psilocybin, the active compound in magic mushrooms, can reduce feelings of loneliness and unresolved grief. Researchers will measure changes in brain activity during a facial emotion recognition task and track social connectedness over time. The trial enrolls medically healthy adults who report high loneliness or grief symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin
What this could lead to
If it works, this could point toward a new way to ease loneliness and grief by targeting how the brain processes social threats.
What could go wrong
This is an early Phase 1 study with only 51 people, so results may not apply broadly. Psilocybin can cause temporary psychological distress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GRIEF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GRIEF LONELINESS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Connecticut Mental Health Center

    New Haven, Connecticut, 06519, United States

    Contact Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.